• 1
    Briggs JD. Causes of death after renal transplantation. Nephrol Dial Transplant 2001; 16: 15451549.
  • 2
    Kasiske BL. Cardiovascular disease after renal transplantation. Semin Nephrol 2000; 20: 176187.
  • 3
    Lindholm A, Albrechtsen D, Frodin L, Tufveson G, Persson NH, Lundgren G. Ischemic heart disease—major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 1995; 60: 451457.
  • 4
    Hamar P, Muller V, Kohnle M et al. Metabolic factors have a major impact on kidney allograft survival. Transplantation 1997; 64: 11351139.
  • 5
    Roodnat JI, Mulder PG, Zietse R et al. Cholesterol as an independent predictor of outcome after renal transplantation. Transplantation 2000; 69: 17041710.
  • 6
    Holdaas H, Fellstrom B, Jardine AG et al. Assessment of lescol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003; 361: 20242031.
  • 7
    Jardine AG, Holdaas H, Fellstrom B et al. ALERT Study Investigators. Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study. Am J Transplant 2004; 4: 988995.
  • 8
    Cosio FG, Pesavento TE, Pelletier RP et al. Patient survival after renal transplantation III: the effects of statins. Am J Kidney Dis 2002; 40: 638643.
  • 9
    Smith S, Blair S, Bonow R et al. AHA/ACC scientific statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 2001; 104: 15771579.
  • 10
    Pearson TA, Blair SN, Daniels SR et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002; 106: 388391.
  • 11
    Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 24862497.
  • 12
    Kiberd B, Keough-Ryan T, Panek R. Cardiovascular disease reduction in the outpatient kidney transplant clinic. Am J Transplant 2003; 3: 13931399.
  • 13
    Kasiske B, Cosio FG, Beto J et al. National Kidney Foundation Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 2004; 4: 1353.
  • 14
    Chmielewski M, Zdrojewski Z, Rutkowski B. Benefits and menaces related to the use of statins in patients after renal transplantation. Ann Transplant 2002; 7: 610.
  • 15
    Sudhop T, Lutjohann D, Kodal A et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002; 106: 19431948.
  • 16
    Ballantyne CM, Houri J, Notarbartolo A et al. Ezetimibe Study Group. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 107: 24092415.
  • 17
    Puthenparumpil JJ, Keough-Ryan T, Kiberd M, Lawen J, Kiberd BA. Treatment of hypercholesterolemia with ezetimibe in the kidney transplant population. Transplant Proc 2005; 37: 10331035.
  • 18
    Koshman SL, Lalonde LD, Burton I, Tymchak WJ, Pearson GJ. Supratherapeutic response to ezetimibe administered with cyclosporine (September). Ann Pharmacother 2005[Epub ahead of print]
  • 19
    Davidson MH, McGarry T, Bettis R et al. Efficacy of simvastatin and ezetimibe in treating hypercholesterolemia. J Am Coll Cardiol 2002; 40: 21352138.
  • 20
    Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 2005; 44: 467494.
  • 21
    García Calvo M, Lisnock J, Bull HG et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A 2005; 102: 81328127.